Sale of wound care platform will benefit CF research
30 Technology has sold the rights to its antimicrobial treatment platform for certain uses, such as for burns and acute wounds, to Convatec. 30 Technology will retain the rights to its wound care platform in other indications, including respiratory diseases such as cystic fibrosis (CF), and will be…